SUMMARY A double-blind cross-over trial was conducted to assess the effects of salbutamol administered by inhalation of dry powder, by tablet, and combined tablet and inhalational powder in a sample of 18 severely asthmatic children. The combined treatment had a rapid onset of effect and sustained action. The onset of action of the tablet treatment was less rapid but sustained, whereas the inhalational powder treatment had rapid onset but fairly short action. The response characteristics of the combined treatment were shown to be an additive function of its tablet and inhaled components. Children on the combined or tablet treatment showed a significant, but slight, increase in pulse rate. Few other side effects were observed.
The ideal drug in the management of asthma has a rapid onset and sustained action. Studies of the response characteristics of inhaled and tablet administered preparations show that both methods fall short of this ideal. Inhaled preparations have a rapid onset of action but tend to lose efficacy rapidly, whereas tablets have a slower onset of action but their effect is more sustained.1-3 Few studies have examined the effects of combination therapy and their results have been conflicting, either indicating an additional benefit without side effects,4 or no significant benefit over inhalational therapy alone and an increased incidence of adverse side effects.5 6 We report on a controlled trial of salbutamol administered by inhalational powder, in a tablet form, and by combined inhalational powder and tablet. The aim was to determine whether the combined tablet and inhalational powder administration produced a treatment having the desired characteristics of rapid onset of effect and sustained action.
Subjects and methods
We studied 18 (10 girls and 8 boys) children aged 5 to 12 (mean 8-3) years who were regular patients at a hospital asthma clinic for severe, recurrent, or chronic asthma (grade C or D).7 Mean duration of symptoms was 5-9 (range 3-9) years. All were receiving continuous bronchodilator treatment and other prophylaxis.
A double-blind cross-over design was used in which the Fig. 2 shows the correspondence between the observed time-response curve for the combined treatment and the time-response curve estimated from the regression equation. It is clear that there is an extremely good fit between the observed and expected values (r = 0 98).
The three preparations were well tolerated but children on combined or tablet treatments showed a slight increase in pulse rate (114.5 versus 109) when compared with those on inhalational powder (F2, 34 = 6.59; P < 0-01). A child with a history of excitability and tachycardia after oral salbutamol responded in this way when given the tablet and combination treatments. Transient tremor was observed in one child on oral treatment and another became excitable for 30 minutes after combination therapy.
Discussion
A combined treatment in which salbutamol was administered both by inhalational powder and by tablet had superior characteristics to either tablet or inhaled treatment alone. 
